Sonoma Pharmaceuticals, Inc. · Surgical & Medical Instruments & Apparatus

SNOA

High riskNext report: Due any day

View price ↗

The short version

A profitable company with growing sales.

Going well

Sales up 60% in the latest quarter vs a year ago
Profitable
Sales up 37% last year

Money moves

No insider buying or selling in the last 30 days
Institutions added 58% to their holdings in the quarter ending June 2026 (5 bought, 7 sold)

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$1.15+1.8% that day

Company value: $6M; Share price times all shares
Price vs sales: 0.25x; No profit over the last year, so this compares value with sales instead
Cash vs value: 97%; A big cushion: cash is a large part of what the company is worth

From SNOA's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 12 quarters, from SEC filings

Sales, Jun '26

$6.4M+60% vs a year earlier

Sep '23Tap a barJun '26

Last 12 months: $21.9M, up 47% from the 12 months before. Over 5 years, sales grew about 0.9% a year.

What the price assumes

Your guesses, our math

Move the sliders to your own view of SNOA. Starting points are the company's recent numbers.

Sales growth+30% a yearRecently: +47% a yearProfit margin4%Last 12 months: 4.2%P/E at the end15xMany steady companies trade at 12x to 25xShare count change0% a yearBelow zero means buybacks; above zero means new shares (dilution)

Sales in 5 years$81M

Profit in 5 years$3M

Price these guesses point to$10.20+787% vs $1.15 todayAbout +55% a year, before dividends

What today's price needs: with a 4% margin and a 15x P/E, sales could shrink about 16% a year for 5 years and still match today's price.

Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

1/6Weak

MissReturn on equity 15%+Earns a lot on the money owners have in the business.0.1%
MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.0.0%
MissProfitable every yearSteady profits, not one good year.4 of 10 years
MissFree cash flow positiveBrings in more cash than it spends to run and grow.-$4.1M
PassShare count not growingNot diluting owners. Falling means buybacks.-0.8% in 3 years
MissGross margin 40%+Pricing power: sells for well above what it costs to make.38.0%

Revenue: $19.5M; +36.7% vs prior year
5-year growth: +0.9%/yr; revenue, per year
Current ratio: 2.88x; short-term assets / bills due
Free cash flow: -$4.1M; -21.1% of revenue

From annual reports filed with the SEC. Not in this company's SEC data, so not scored: debt under half of equity. A checklist is a starting point for research, not a verdict.

Latest quarter

Quarter ended Jun 30, 2026

Reported Nov 8, 2018

Revenue: $6.4M; +59.6% YoY
EPS: -$0.09; vs -$0.76
Op. margin: -0.6%; +26.7 pts
Gross margin: 40.2%; +3.7 pts
Free cash flow: -$651K
Share count: +134.4%; vs a year ago

Insider rating

Last 90 days

No open-market insider buys or sells in the last 90 days.

Weekly insider trend

No trades to chart yet.

Filing buzz

Last 7 days vs normal

0/ 100

This week: 0
Normal week: 0.5
vs normal: 0.0x

SEC filings of any kind. 50 means a normal week.

Institutional ownership

Steady+58.2%

Institutions added 58.2% to their holdings. 5 bought, 7 sold.

Shares held by institutions111K

Sep '24Jun '26

Safety check

From SEC filings

Share count growthYearly rate, last 3 years

+141.4%

Cash runwayAt last year's cash burn

16 months

Debt to equityLatest balance sheet: debt compared with what owners have

Total liabilities $11.5M

Shares outstandingLatest reported

Why high risk

Losing money
About 16 months of cash left at its current burn
Share count growing 141.4% a year (dilution)
1 offering filing in 6 months (may sell new shares)

Earnings reports

Last 12

Next reportDue any dayEstimated from the same quarter last year

Results filedNov 8, 2018
Results filedAug 8, 2018
Results filedJun 13, 2018
Results filedFeb 7, 2018
Results filedNov 9, 2017

Flags and big holders

Offerings 6 months, flags 12 months, holders 90 days

Offering prospectusJun 18 · View filing ↗Offering

Insider trades

Open-market buys and sells, last 90 days

No open-market buys or sells in 90 days. Grants and option exercises are left out.

"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.

Latest filings

Straight from SEC EDGAR

Major agreementOct 6 · Form 8-K ↗8-A12B/AOct 6 · Form 8-A12B/A ↗Shareholder vote resultsSep 17 · Form 8-K ↗Shareholder vote resultsAug 19 · Form 8-K ↗Quarterly reportAug 6 · Form 10-Q ↗Proxy statementJul 28 · Form DEF 14A ↗DEFA14AJul 23 · Form DEFA14A ↗Employee stock plan registrationJul 9 · Form S-8 ↗

Stock awardPoggetto John DalController

7,500 shares

+30% of holdings
Now owns 32,750 shares
Restricted Stock Units
Filed same day

Jul 9Form 4 ↗

Stock awardJerome J DvonchChief Financial Officer

10,000 shares

+29% of holdings
Now owns 44,391 shares
Restricted Stock Units
Filed same day

Jul 9Form 4 ↗

Stock awardVanessa JacobyDirector

10,000 shares

+100% of holdings
Now owns 20,000 shares
Exercise price $1.26
Stock option (right to buy)
Filed same day

Jul 9Form 4 ↗

Stock awardJohn MclaughlinDirector

10,000 shares

+50% of holdings
Now owns 30,001 shares
Exercise price $1.26
Stock option (right to buy)
Filed same day

Jul 9Form 4 ↗

Stock awardAmy Moss TromblyChief Executive Officer

10,000 shares

+24% of holdings
Now owns 52,185 shares
Restricted Stock Units
Filed same day

Jul 9Form 4 ↗

Stock awardPhilippe WeigerstorferDirector

10,000 shares

+50% of holdings
Now owns 30,001 shares
Exercise price $1.26
Stock option (right to buy)
Filed same day

Jul 9Form 4 ↗

DEFA14AJun 24 · Form DEFA14A ↗

Source: SEC EDGAR filings. For informational purposes. Not investment advice.

Report a problem with this page